What is the most likely cause of the firm, waxy, non-painful, and non-itchy lesions on the lower abdomen of a patient with a history of Human Immunodeficiency Virus (HIV) infection, managed with combination therapy and Bactrim (trimethoprim/sulfamethoxazole), that become irritated with friction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 10, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Viral Infection (Molluscum Contagiosum)

The most likely cause of these firm, waxy, non-painful, non-itchy umbilicated papules on the lower abdomen in an HIV-positive patient is a viral infection, specifically molluscum contagiosum (MC), which represents a cutaneous marker of severe immunosuppression in this population. 1, 2, 3

Clinical Reasoning

Characteristic Features Supporting Viral Etiology

The clinical presentation is pathognomonic for molluscum contagiosum:

  • Waxy, firm papules with umbilication are the hallmark appearance of MC lesions, described as smooth-surfaced, spherical papules with central umbilication 1
  • Non-painful and non-itchy nature distinguishes MC from inflammatory conditions, though friction irritation (as described with clothing contact) is typical 1
  • Location on lower abdomen is consistent with MC distribution in HIV patients, where lesions commonly occur on the trunk and may be associated with sexual transmission patterns 3

HIV-Specific Context

The patient's HIV status is critical to this diagnosis:

  • MC occurs in 5-10% of HIV-infected patients and represents a late manifestation of HIV infection, serving as a cutaneous correlate of cellular immune deficiency 4, 3
  • Severe immunosuppression correlation: MC in HIV patients typically occurs with CD4+ counts below 100 cells/mm³, with an inverse relationship between CD4+ count and number of lesions (mean CD4+ count of 85.7/mm³ in one series) 3
  • Extensive and persistent disease: Unlike immunocompetent patients where MC resolves in 6 months to 5 years, HIV-coinfected patients develop more extensive, severe, and treatment-resistant lesions 1, 4

Excluding Alternative Diagnoses

Why Not Fungal Infection?

  • Fungal infections (dermatophytes, candida) typically present with scaling, erythema, and pruritus—none of which are described 2
  • The waxy, umbilicated appearance is not characteristic of fungal lesions

Why Not Malignancy?

  • While MC can mimic cutaneous tumors in HIV patients, the multiple nature, characteristic waxy appearance, and umbilication favor benign viral infection 1
  • Skin biopsy would be indicated if concern for dimorphic fungal infections or malignancy exists, particularly with atypical presentations 2

Why Not Medication Reaction?

  • Neither combination antiretroviral therapy nor Bactrim typically causes firm, waxy, umbilicated papules
  • Drug reactions usually present with erythema, pruritus, or urticarial features

Why Not Skin Irritant Reaction?

  • Contact dermatitis presents with erythema, vesiculation, and pruritus
  • The chronic, firm, waxy nature of these lesions is inconsistent with irritant contact dermatitis

Clinical Management Implications

Diagnostic Confirmation

  • Skin biopsy is important to rule out dimorphic fungal infections in HIV patients with facial or extensive lesions, particularly when CD4 counts are severely depressed 2
  • Clinical diagnosis alone may be sufficient for typical presentations

Treatment Considerations

  • Immune reconstitution is key: Resolution of disseminated MC occurs 5-6 months after initiating highly active antiretroviral therapy (HAART), making optimization of HIV treatment the primary intervention 4, 5
  • Local destructive therapies include curettage with topical 70% trichloroacetic acid (good response observed with three sessions) 2
  • Photodynamic therapy with 5-aminolevulinic acid has shown substantial reduction in lesion count and severity in HIV-coinfected patients, though additional research is needed 1
  • Traditional therapies are often unsatisfactory in immunocompromised patients until immune function improves 1

Prognostic Marker

  • MC serves as a cutaneous marker of severe immunosuppression, indicating the need for aggressive HIV management and monitoring for other opportunistic infections 2, 3
  • The presence of MC suggests CD4+ counts are likely below 100 cells/mm³, warranting evaluation for other AIDS-defining conditions 3

References

2
Research

Molluscum contagiosum eyelid lesions in an HIV-patient.

Dermatology online journal, 2013

Related Questions

What is the initial management approach for a patient with Polycystic Ovary Syndrome (PCOS)?
Is buprenorphine (opioid partial agonist) effective for treating complex regional pain syndrome (CRPS)?
For a 40-year-old postmenopausal woman, status post surgical menopause, without a uterus, experiencing difficulty with transdermal estrogen therapy due to hyperhidrosis (excessive sweating), is oral estrogen therapy a recommended alternative for managing menopausal symptoms?
What is the best approach for switching a patient with complex regional pain syndrome (CRPS) and a history of opioid use from hydromorphone to buprenorphine (Subutex)?
What are the indications for paracetamol (acetaminophen) infusion in patients, including those with liver disease or unable to take oral medication?
Is it safe to administer hydroxyzine (antihistamine) 50 mg and Benadryl (diphenhydramine) 50 mg concurrently to an adult patient with no known medical history or allergies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question